Champions Oncology, Inc.

Greetings. Welcome to the Champions Oncology first quarter fiscal year 2026 earnings call. At this time, all participants are in a listen-only mode. A question and answer session will follow the formal presentation. If anyone should require operator assistance during the conference, please press star zero on your telephone keypad. Please note, this conference is being recorded. I will now turn the conference over to your host, Rob Brannon, Chief Executive Officer. You may begin.

Good afternoon.

I'm Rob Brennan, CEO of Champions Oncology, and I'm joined today by our CFO, David Miller. Thank you for joining our quarterly earnings call. Before we begin, I'll remind you that today's remarks may include forward-looking statements. Actual results may differ materially, and more information can be found in our filings with the SEC. As many of you know fiscal 2025 is a pivotal year for champions, as we rebounded after difficult 2024 to achieve record annual revenue and profitability. Now, as we move into fiscal year 2026 i'm honored to step into the role of leading champions forward. My focus is on building on the strong foundation sharpening strategic execution positioning champions for sustainable long term growth. Having been on the board of directors of Champions Oncology, I have been intimately involved with Ronnie in shaping the strategy, which is strong and will remain consistent. Together, we are committed to driving the large value opportunities we see in Corellia and in our data business while continuing to expand our core TOS platform, which remains the heart and soul of Champions. Turning to the first quarter of fiscal 2026, the company delivered $14 million in revenue, rebounding from temporary softness in Q4. Growth was led by our TOS business with meaningful contributions from our emerging data platform. The momentum we built in fiscal 2025 has carried into this year, reinforcing our confidence and continued top-line growth. Our foundation remains our industry-leading PDX bank with its steep multi-omic characterization. This unique resource continues to empower pharmacology studies across biopharma. The macro environment is still challenging, with biotech funding and R&D budgets still under pressure. We are encouraged by improving trends. Customer cancellations are down, bookings to revenue conversion has increased, and our growing relationships with large pharma are creating opportunities for larger, more durable bookings. We're also excited about the progress in our radio pharmaceutical services platform. Backed by our expanded radioactive materials license, new radiochemistry infrastructure, and more than 30 screened PDX models, we can now deliver fully integrated workflows, from biodistribution to efficacy testing, on clinically relevant tumor models. Strategically, this expands our customer offering in a fast-growing field while also reducing costs and improving gross margins by bringing work in-house. Our data platform is also gaining momentum. Since closing our first licensing deal less than a year ago, We've now generated data sales for three consecutive quarters. By leveraging our uniquely characterized PDX bank, we're creating the most comprehensive and clinically relevant tumor data set in the industry. As AI and machine learning become increasingly central to drug discovery, we see significant long-term opportunity in this business. Finally, Corellia, our wholly-owned drug discovery subsidiary, continues to advance. The data emerging from our platform and in vivo experiments is compelling, and despite the funding headwinds in biotech, we remain confident this work will translate into meaningful investment opportunities in the future. In summary, Q1 was a solid start to fiscal 2026. We returned to growth, advanced our strategic initiatives in radiopharma and data, and reinforced the foundation for long-term success. On a personal note, I'm grateful for the opportunity to lead champions into this next chapter, and I want to thank we have in place, I'm confident in our ability to execute and deliver lasting value for our shareholders. And now I'll turn it over to David Miller to discuss our financial results.